Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 2/2017

01-02-2017 | Original Article

Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model

Authors: W. Ni, Y. Jiang

Published in: Osteoporosis International | Issue 2/2017

Login to get access

Abstract

Summary

This study used a simulation model to determine the cost-effective threshold of fracture risk to treat osteoporosis among elderly Chinese women. Osteoporosis treatment is cost-effective among average-risk women who are at least 75 years old and above-average-risk women who are younger than 75 years old.

Introduction

Aging of the Chinese population is imposing increasing economic burden of osteoporosis. This study evaluated the cost-effectiveness of osteoporosis treatment among the senior Chinese women population.

Methods

A discrete event simulation model using age-specific probabilities of hip fracture, clinical vertebral fracture, wrist fracture, humerus fracture, and other fracture; costs (2015 US dollars); and quality-adjusted life years (QALYs) was used to assess the cost-effectiveness of osteoporosis treatment. Incremental cost-effectiveness ratio (ICER) was calculated. The willingness to pay (WTP) for a QALY in China was compared with the calculated ICER to decide the cost-effectiveness. To determine the absolute 10-year hip fracture probability at which the osteoporosis treatment became cost-effective, average age-specific probabilities for all fractures were multiplied by a relative risk (RR) that was systematically varied from 0 to 10 until the WTP threshold was observed for treatment relative to no intervention. Sensitivity analyses were also performed to evaluate the impacts from WTP and annual treatment costs.

Results

In baseline analysis, simulated ICERs were higher than the WTP threshold among Chinese women younger than 75, but much lower than the WTP among the older population. Sensitivity analyses indicated that cost-effectiveness could vary due to a higher WTP threshold or a lower annual treatment cost. A 30 % increase in WTP or a 30 % reduction in annual treatment costs will make osteoporosis treatment cost-effective for Chinese women population from 55 to 85.

Conclusions

The current study provides evidence that osteoporosis treatment is cost-effective among a subpopulation of Chinese senior women. The results also indicate that the cost-effectiveness of using osteoporosis treatment is sensitive to the WTP threshold and annual treatment costs.
Appendix
Available only for authorised users
Literature
1.
Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeus N, Pfleger B, Khaltaev N (2005) Assessment of fracture risk. Osteoporos Int 16:581–589CrossRefPubMed
2.
Kanis JA, Black D, Cooper C, et al. (2002) A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int 13:527–536CrossRefPubMed
3.
1998) Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Introduction. Osteoporos Int 8(Suppl 4):S7–80
4.
Jiang Y, Ni W (2015) Expected lifetime numbers, risks, and burden of osteoporotic fractures for 50-year old Chinese women: a discrete event simulation incorporating FRAX. J Bone Miner Metab
5.
6.
Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767CrossRefPubMed
7.
Liang H, ZHONG W, Ning L (2009) Statistics on the expenses for medical care of osteoporotic fractures in Beijing Jishuitan Hospital (from 2000 to 2006)[J]. Journal of Practical Orthopaedics 5:000
8.
Mithal A, Ebeling P, Kyer C (2013) The Asia-Pacific regional audit: epidemiology, costs, and burden of osteoporosis in 2013. International osteoporosis foundation
9.
Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468–473CrossRefPubMed
10.
Hasegawa Y, Suzuki S, Wingstrand H (2007) Risk of mortality following hip fracture in Japan. J Orthop Sci 12:113–117CrossRefPubMed
11.
Lips P, van Schoor NM (2005) Quality of life in patients with osteoporosis. Osteoporos Int 16:447–455CrossRefPubMed
12.
Jansen JP, Bergman GJ, Huels J, Olson M (2011) The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum 40(275–284):e271–e272
13.
Johnell O, Jonsson B, Jonsson L, Black D (2003) Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. PharmacoEconomics 21:305–314CrossRefPubMed
14.
Strom O, Borgstrom F, Sen SS, Boonen S, Haentjens P, Johnell O, Kanis JA (2007) Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries—an economic evaluation based on the fracture intervention trial. Osteoporos Int 18:1047–1061CrossRefPubMed
15.
Zhang Z, Ou Y, Sheng Z, Liao E (2014) How to decide intervention thresholds based on FRAX in central south Chinese postmenopausal women. Endocrine 45:195–197CrossRefPubMed
16.
Bleibler F, Rapp K, Jaensch A, Becker C, Konig H-H (2014) Expected lifetime numbers and costs of fractures in postmenopausal women with and without osteoporosis in Germany: a discrete event simulation model. BMC Health Serv Res 14:284CrossRefPubMedPubMedCentral
17.
Caro JJ (2005) Pharmacoeconomic analyses using discrete event simulation. PharmacoEconomics 23:323–332CrossRefPubMed
18.
Kung AW, Lee KK, Ho AY, Tang G, Luk KD (2007) Ten-year risk of osteoporotic fractures in postmenopausal Chinese women according to clinical risk factors and BMD T-scores: a prospective study. J Bone Miner Res 22:1080–1087CrossRefPubMed
19.
Hiligsmann M, Ethgen O, Bruyère O, Richy F, Gathon HJ, Reginster JY (2009) Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 12:687–696CrossRefPubMed
20.
Borgström F (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 21:495–505CrossRefPubMed
21.
Borgström F, Ström O, Kleman M, McCloskey E, Johansson H, Odén A, Kanis J (2011) Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective. Osteoporos Int 22:955–965CrossRefPubMed
22.
Kim K, Svedbom A, Luo X, Sutradhar S, Kanis J (2014) Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm. Osteoporos Int 25:325–337CrossRefPubMed
23.
Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA, Manitoba Bone Density P (2012) Does osteoporosis therapy invalidate FRAX for fracture prediction? J Bone Miner Res 27:1243–1251CrossRefPubMed
24.
Liao E-Y, Wu X-P, Deng X-G, Huang G, Zhu X-P, Long Z-F, Wang W-B, Tang W-L, Zhang H (2002) Age-related bone mineral density, accumulated bone loss rate and prevalence of osteoporosis at multiple skeletal sites in Chinese women. Osteoporos Int 13:669–676CrossRefPubMed
25.
Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP (1982) A convenient approximation of life expectancy (the “DEALE”): II. Use in medical decision-making The American journal of medicine 73:889–897PubMed
26.
Fang X, Shi J, Song X, Mitnitski A, Tang Z, Wang C, Yu P, Rockwood K (2012) Frailty in relation to the risk of falls, fractures, and mortality in older Chinese adults: results from the Beijing Longitudinal Study of Aging. J Nutr Health Aging 16:903–907CrossRefPubMed
27.
28.
Wang C-B, Lin C-FJ, Liang W-M, Cheng C-F, Chang Y-J, Wu H-C, Wu T-N, Leu T-H (2013) Excess mortality after hip fracture among the elderly in Taiwan: a nationwide population-based cohort study. Bone 56:147–153CrossRefPubMed
29.
Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15:108–112CrossRefPubMed
30.
Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513–521CrossRefPubMed
31.
Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL, National Osteoporosis Foundation Guide C (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447CrossRefPubMedPubMedCentral
32.
Hwang JS, Chin LS, Chen JF, Yang TS, Chen PQ, Tsai KS, Leung PC (2011) The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis. J Bone Miner Metab 29:328–333CrossRefPubMed
33.
Sun S, Chen J, Johannesson M, Kind P, Xu L, Zhang Y, Burström K (2011) Population health status in China: EQ-5D results, by age, sex and socio-economic status, from the National Health Services Survey 2008. Qual Life Res 20:309–320CrossRefPubMed
34.
35.
Qu B, Ma Y, Yan M, Wu H-H, Fan L, Liao D-F, Pan X-M, Hong Z (2014) The economic burden of fracture patients with osteoporosis in western China. Osteoporos Int 25:1853–1860CrossRefPubMed
36.
Shih V, Chan A, Xie F, Ko Y (2012) Health state utility assessment for breast cancer. Value in Health Regional Issues 1:93–97CrossRef
37.
Hagino H, Nakamura T, Fujiwara S, Oeki M, Okano T, Teshima R (2009) Sequential change in quality of life for patients with incident clinical fractures: a prospective study. Osteoporos Int 20:695–702CrossRefPubMed
38.
39.
40.
41.
Zhao F-L, Yue M, Yang H, Wang T, Wu J-H, Li S-C (2011) Willingness to pay per quality-adjusted life year: is one threshold enough for decision-making?: results from a study in patients with chronic prostatitis. Med Care 49:267–272CrossRefPubMed
42.
Moriwaki K, Komaba H, Noto S, Yanagisawa S, Takiguchi T, Inoue H, Toujo T, Fukagawa M, Takahashi HE (2013) Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan. J Bone Miner Res 28:395–403CrossRefPubMed
43.
Kling JM, Clarke BL, Sandhu NP (2014) Osteoporosis prevention, screening, and treatment: a review. J Women’s Health (Larchmt) 23:563–572CrossRef
44.
Kanis JA, Johnell O, Oden A, Borgstrom F, Johansson H, De Laet C, Jonsson B (2005) Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos Int 16:6–14CrossRefPubMed
45.
Caro JJ, Möller J, Getsios D (2010) Discrete event simulation: the preferred technique for health economic evaluations? Value Health 13:1056–1060CrossRefPubMed
46.
Van Gestel A, Severens JL, Webers CA, Beckers HJ, Jansonius NM, Schouten JS (2010) Modeling complex treatment strategies: construction and validation of a discrete event simulation model for glaucoma. Value Health 13:358–367CrossRefPubMed
Metadata
Title
Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model
Authors
W. Ni
Y. Jiang
Publication date
01-02-2017
Publisher
Springer London
Published in
Osteoporosis International / Issue 2/2017
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-016-3751-z

Other articles of this Issue 2/2017

Osteoporosis International 2/2017 Go to the issue

Original Article

Do osteoporotic fractures constitute a greater recalcitrant challenge for skeletal regeneration? Investigating the efficacy of BMP-7 and zoledronate treatment of diaphyseal fractures in an open fracture osteoporotic rat model

Letter

Further major uncorrected errors in National Osteoporosis Foundation meta-analyses of calcium and vitamin D supplementation in fracture prevention

Original Article

A pilot randomized controlled trial of a decision aid with tailored fracture risk tool delivered via a patient portal

Review

Bone imaging in hypoparathyroidism

Original Article

Bone mineral density and microarchitecture in patients with essential thrombocythemia and polycythemia vera

Original Article

Higher serum sclerostin levels and insufficiency of vitamin D are strongly associated with vertebral fractures in hemodialysis patients: a case control study